Naurex Lands $38,000,000 Series B Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=22c6625e-55ff-47d3-9b6f-3c65b01211b6&Preview=1 -
Date
12/17/2012 -
Company Name
Naurex -
Mailing Address
1801 Maple Ave. Evanston, IL 60201 -
Company Description
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). -
Website
http://www.naurex.com -
Transaction Type
Venture Equity -
Transaction Amount
$38,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Naurex will use the proceeds from the Series B financing to fund a number of key programs from its NMDA receptor modulator platform, including conducting a Phase Ilb trial of GLYX-13, the company’s lead NMDA receptor modulator in development for the treatment of depression, advancing its second-generation compound NRX-1074 into Phase I and Il clinical trials in depression and further developing its second- and third-generation programs for other CNS disorders. -
M&A Terms
-
Venture Investor
Baxter Ventures -
Venture Investor
Adams Street Partners -
Venture Investor
Latterell Venture Partners -
Venture Investor
Genesys Capital -
Venture Investor
Lundbeckfond Ventures -
Venture Investor
Takeda Ventures -
Venture Investor
Shire Pharmaceuticals
